Case study: Discovering Oral Obesity Drug targeting TNIK.

Challenge

Obesity remains without an FDA-approved therapy targeting TNIK, presenting a significant unmet need and an opportunity for a first-in-class treatment.

Solution & Impact

We used a combination of BIOPTIC B1 and B2 models, achieving ~8% hit rate over two iterations and identifying multiple novel chemical scaffolds with high potential for targeting TNIK. This advancement opens the door to pioneering obesity therapy, positioning us at the forefront of first-in-class drug discovery in this critical area.

References

1. TNIK is a conserved regulator of glucose and lipid metabolism in obesity

2. TNIK’s emerging role in cancer, metabolism, and age-related diseases